Sphere Fluidics announces enhanced Cyto-Mine capability and performance

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced it has enhanced the capability and performance of its Cyto-Mine® System. The simplified design offers improved functionality to help streamline workflows, reduce costs, increase throughput, and enable high-value clones to be captured in a single run.

Cyto-Mine® Operations Guide

Sphere Fluidics’ Cyto-Mine is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification. It is now faster and easier to manufacture, commission and service as a result of a simplified internal design. The new electronics design improves system performance, reliability, and stability, while the updated software features help to provide a better user experience, reduce user-instrument interaction, and allow for more robust data analysis.

The enhanced capability and performance for the instrument, enables users to access more functionality and the improved software offers a more advanced and reliable system to help further simplify antibody discovery, cell line development, cell therapy, and synthetic biology workflows.

Dr. Marian Rehak, VP of Research and Development at Sphere Fluidics, said: “The new design is the culmination of 18 months' hard work by our R&D team. Due to the deployment of these latest improvements, researchers are now able to perform even faster selective screening of single cells to find rare lead candidates. Although, principally designed for antibody discovery and cell line development, the platform is very flexible and has now been demonstrated to be useful in a wide variety of application areas.”

The new Cyto-Mine design not only unlocks increased functionality for scientists but is also faster to manufacture, commission, and service. A new user can learn how to run our user-friendly software within a single working day.

We are helping our users to simplify their workflows with the added operational benefit of enhancing our service and support capacity.”

Rob Treanor, Operations Director at Sphere Fluidics


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sphere Fluidics. (2021, May 17). Sphere Fluidics announces enhanced Cyto-Mine capability and performance. News-Medical. Retrieved on November 29, 2023 from https://www.news-medical.net/news/20210517/Sphere-Fluidics-announces-enhanced-Cyto-Mine-capability-and-performance.aspx.

  • MLA

    Sphere Fluidics. "Sphere Fluidics announces enhanced Cyto-Mine capability and performance". News-Medical. 29 November 2023. <https://www.news-medical.net/news/20210517/Sphere-Fluidics-announces-enhanced-Cyto-Mine-capability-and-performance.aspx>.

  • Chicago

    Sphere Fluidics. "Sphere Fluidics announces enhanced Cyto-Mine capability and performance". News-Medical. https://www.news-medical.net/news/20210517/Sphere-Fluidics-announces-enhanced-Cyto-Mine-capability-and-performance.aspx. (accessed November 29, 2023).

  • Harvard

    Sphere Fluidics. 2021. Sphere Fluidics announces enhanced Cyto-Mine capability and performance. News-Medical, viewed 29 November 2023, https://www.news-medical.net/news/20210517/Sphere-Fluidics-announces-enhanced-Cyto-Mine-capability-and-performance.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Sphere Fluidics strengthens commercial team with three new senior hires